Global Oncology Academy

Current Treatment Paradigms in Colorectal Cancer (CRC)

    The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology a...

    Available credits: 1.00


    Valid until:

    Take Post-Test

    If you’ve already completed the activity.

    • Overview

      The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology and signal pathways. However, a significant proportion of patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck has a poor prognosis, in many cases due to late presentation. For those patients, cure is typically not possible; treatment options can prolong life and improve symptoms.  Thus, long-term survival rates in these metastatic settings, while improving, remain unacceptably low.

      Despite advances, the management of patients with metastatic disease continues to present challenges for clinicians. As innovative focused therapeutic options become available and treatment paradigms evolve, the need to discern when and how to incorporate these promising agents into clinicians’ armamentarium presents a great educational need. Moreover, continuing advances in our understanding of cancer pathophysiology, molecular pathways, the optimal and sequential use of targeted therapies in the context of chemotherapy and radiotherapy in the metastatic setting and the therapeutic potential of investigational agents currently being explored for various cancers, suggest educational and clinical practice gaps that must be effectively addressed to further improve outcomes in patients with cancer.

      Given this information, TOPEC Global is pleased to present this module titled “Current Treatment Paradigms in Colorectal Cancer (CRC).” This module reviews the burden of CRC and its early-stage management, including adjuvant therapy, how to achieve resection in locally-advanced and metastatic CRC, the treatment of unresectable metastatic CRC, and how to optimise CRC outcomes through use of personalized medicine.

    • Learning Objectives

      At the completion of this module, participants will be better able to:

      1. Describe the socio-economic burdens of CRC
      2. Incorporate the principles and management of early-stage CRC into their clinical practice
      3. Assess and apply strategies that improve resectability in CRC
      4. Optimise treatment approaches for unresectable metastatic CRC
      5. Improve the continuum of treatment in CRC through use of personalized medicine
    • Target Audience

      This course is designed to meet the Continuing Medical Education needs of oncologists, surgical oncologists and radiotherapists.

    • Commercial Support

      This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
      Original Release Date: 
      24 September 2015
      Expiration Date: 21 January 201

    • Accreditation and Credit Designation Statements

      Current Treatment Paradigms in Colorectal Cancer (CRC), made available on and organized by Siyemi Learning and TOPEC Global, LLC, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

      The course, Current Treatment Paradigms in Colorectal Cancer (CRC),  made available on and organized by Siyemi Learning and TOPEC Global, LLC, is awarded 1 European CME credits (ECMEC). Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME credit to AMA credit can be found at

      Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

      Contact Information
      In case of technical needs, please contact:

    • Disclosure of Conflicts of Interest


      Jan B. Vermorken, MD, PhD
      Emeritus Professor of Oncology
      Department of Medical Oncology 
      Antwerp University Hospital 
      Edegem, Belgium
      Financial Relationship Disclosure
      Consultant: Amgen, Genentech, Merck Serono, Shionogi      
      Commercial Interest Speakers Bureau: Merck Serono


      Fortunato Ciardiello, MD, PhD
      Professor of Medical Oncology
      Director of Dipartmento Medico
      Chirurgico di Internistica Clinica e Sperimentale
      Seconda Università degli Studi di Napoli
      Naples, Italy
      Financial Relationship Disclosure
      Consultant: Bayer HealthCare Pharmaceuticals, Merck Serono, Roche
      Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals

      Joel Guigay, MD, PhD
      Director of Cancer Center
      Centre Antoine Lacassagne
      Nice, France
      Financial Relationship Disclosure
      Contracted Research: Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono

    • System Requirements

      Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

    Facebook Comments